1-3 of 3
Andrew McMillan
Close
Sort by
Journal Articles

Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data

Clinical Trials & Observations
Laurie H. Sehn, Mark Hertzberg, Stephen Opat, Alex F. Herrera, Sarit Assouline, Christopher R. Flowers, Tae Min Kim, Andrew McMillan, Muhit Ozcan, Violaine Safar, Gilles Salles, Grace Ku, Jamie Hirata, Yi Meng Chang, Lisa Musick, Matthew J. Matasar
Journal: Blood Advances
Blood Adv (2022) 6 (2): 533–543.
https://doi.org/10.1182/bloodadvances.2021005794
Published: 2022
Includes: Supplemental data
Journal Articles

Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP

Clinical Trials & Observations
Toby A. Eyre, William Wilson, Amy A. Kirkwood, Julia Wolf, Catherine Hildyard, Hannah Plaschkes, John Griffith, Paul Fields, Arief Gunawan, Rebecca Oliver, Stephen Booth, Jaimal Kothari, Christopher P. Fox, Nicolas Martinez-Calle, Andrew McMillan, Mark Bishton, Graham P. Collins, Chris S. R. Hatton
Journal: Blood Advances
Blood Adv (2021) 5 (8): 2229–2236.
https://doi.org/10.1182/bloodadvances.2021004286
Published: 2021
Includes: Supplemental data
Journal Articles

Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphoma

Clinical Trials & Observations
Tim M. Illidge, Elizabeth H. Phillips, Nicholas Counsell, Ruth Pettengell, Peter W. M. Johnson, Dominic J. Culligan, Bilyana Popova, Laura Clifton-Hadley, Andrew McMillan, Peter Hoskin, Sally F. Barrington, John Radford
Journal: Blood Advances
Blood Adv (2020) 4 (1): 203–206.
https://doi.org/10.1182/bloodadvances.2019001023
Published: 2020
Includes: Supplemental data